Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islet Transplantation Using a T-Cell Depleting Immunosuppression Induction Regimen
NCT01909245Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jul 2015
- Primary completion
- Aug 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of allogenic human islet cells in type 1 diabetes mellitus (T1D), sponsored by City of Hope. Started Jul 2015; status: active, not recruiting.
02
Drugs
allogenic human islet cells
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01909245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01909245.